The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.

Key opinion leaders explores the management of gastrointestinal side effects in patients on osimertinib, focusing on ...

Medical experts compare the adverse event profile of lorlatinib to other ALK inhibitors like alectinib and brigatinib, ...

Medical experts discuss approaches to dose modifications and treatment interruptions for adverse events with ALK inhibitors, ...

Key opinion leaders discusses strategies for handling gastrointestinal side effects in patients taking osimertinib, including ...

Given the evolving role of trastuzumab deruxtecan (Enhertu) in the treatment of breast cancer, especially those who are HER2 ...

Tislelizumab Plus Chemo Demonstrates Activity and Tolerability in Advanced Gastric/GEJ Cancer ...

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Tislelizumab Plus Chemo Demonstrates Activity and Tolerability in Advanced Gastric/GEJ Cancer ...

Tislelizumab Plus Chemo Demonstrates Activity and Tolerability in Advanced Gastric/GEJ Cancer ...

Ribociclib plus endocrine therapy shows PFS benefit in luminal B/HER2E breast cancer subtypes compared to chemotherapy, especially with low immune-related gene expression.

Palliative care is often associated with a patient entering end of life treatment and giving up on their treatment, but that ...